Overview

TAK-071 Scopolamine-Induced Cognitive Impairment Study

Status:
Terminated
Trial end date:
2017-08-08
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess the effect of a single oral dose of TAK-071 on the attenuation of cognitive deficit induced by scopolamine as measured by Groton Maze Learning Test (GMLT) (total number of errors).
Phase:
Phase 1
Details
Lead Sponsor:
Takeda
Treatments:
Butylscopolammonium Bromide
Donepezil
Scopolamine
Scopolamine Hydrobromide